{
  "nct_ids": [
    "NCT01922921",
    "NCT01026116",
    "NCT06650748",
    "NCT00109785",
    "NCT00616135"
  ],
  "processing_type": "concurrent_process_trials",
  "summary": {
    "total_trials": 5,
    "successful_trials": 5,
    "failed_trials": 0,
    "success_rate": 100.0,
    "duration_seconds": 2.005336046218872,
    "processing_rate": 2.4933476907412433
  },
  "task_statistics": {
    "total_tasks": 5,
    "completed_tasks": 5,
    "successful_tasks": 5,
    "failed_tasks": 0,
    "completion_rate": 1.0,
    "success_rate": 1.0,
    "workers_running": 20,
    "queue_size": 0
  },
  "successful_trials": [
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01922921",
          "orgStudyIdInfo": {
            "id": "7866"
          },
          "secondaryIdInfos": [
            {
              "id": "NCI-2013-01377",
              "type": "REGISTRY",
              "domain": "CTRP (Clinical Trial Reporting Program)"
            },
            {
              "id": "135"
            },
            {
              "id": "7866/135"
            },
            {
              "id": "7866",
              "type": "OTHER",
              "domain": "Fred Hutch/University of Washington Cancer Consortium"
            },
            {
              "id": "P30CA015704",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/P30CA015704"
            },
            {
              "id": "U19AT006028",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/U19AT006028"
            }
          ],
          "organization": {
            "fullName": "University of Washington",
            "class": "OTHER"
          },
          "briefTitle": "Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy",
          "officialTitle": "Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK\u00ae) Concurrently With a HER2 ICD Peptide-Based Vaccine in Patients With Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy"
        },
        "statusModule": {
          "statusVerifiedDate": "2023-04",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2014-02-05",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-10-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-09-01",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2013-08-01",
          "studyFirstSubmitQcDate": "2013-08-12",
          "studyFirstPostDateStruct": {
            "date": "2013-08-14",
            "type": "ESTIMATED"
          },
          "resultsFirstSubmitDate": "2022-12-13",
          "resultsFirstSubmitQcDate": "2023-04-15",
          "resultsFirstPostDateStruct": {
            "date": "2023-04-18",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2023-04-15",
          "lastUpdatePostDateStruct": {
            "date": "2023-04-18",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "William Rayford Gwin III, MD",
            "investigatorTitle": "Assistant Professor",
            "investigatorAffiliation": "University of Washington"
          },
          "leadSponsor": {
            "name": "University of Washington",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "National Cancer Institute (NCI)",
              "class": "NIH"
            },
            {
              "name": "National Center for Complementary and Integrative Health (NCCIH)",
              "class": "NIH"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "This randomized phase I/II trial studies the side effects of vaccine therapy with or without polysaccharide-K and to see how well it works in treating patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer who are receiving HER2-targeted monoclonal antibody therapy. Vaccines made from HER2 intracellular domain (ICD) peptide may help the body build an effective immune response to kill tumor cells that express HER2. Polysaccharide-K may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether vaccine therapy works better when given with or without polysaccharide-K in treating breast cancer.",
          "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To evaluate the safety of polysaccharide-K (PSK) when given with HER2-directed immunotherapy.\n\nSECONDARY OBJECTIVES:\n\nI. To evaluate the effect of PSK on natural killer (NK) cell functional activity when given with HER2-directed immunotherapy.\n\nTERTIARY OBJECTIVES:\n\nI. To investigate the effect of PSK when given with HER2-directed immunotherapy on: serum levels of pro-inflammatory cytokine and/or chemokines; intermolecular epitope spreading; serum transforming growth factor (TGF)-beta levels; progression free survival (PFS) and overall survival (OS).\n\nOUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\nARM I: Patients receive HER2 ICD peptide-based vaccine intradermally (ID) once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo orally (PO) twice daily (BID) for 4 months.\n\nARM II: Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.\n\nAfter completion of study treatment, patients are followed up for 9 months and then twice annually for 3 years."
        },
        "conditionsModule": {
          "conditions": [
            "HER2/Neu Positive",
            "Recurrent Breast Carcinoma",
            "Stage IV Breast Cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "PARALLEL",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "DOUBLE",
              "whoMasked": [
                "PARTICIPANT",
                "INVESTIGATOR"
              ]
            }
          },
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Arm I (placebo)",
              "type": "ACTIVE_COMPARATOR",
              "description": "Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.",
              "interventionNames": [
                "Biological: HER-2/neu Intracellular Domain Protein",
                "Other: Laboratory Biomarker Analysis",
                "Biological: Pertuzumab",
                "Other: Placebo",
                "Biological: Trastuzumab"
              ]
            },
            {
              "label": "Arm II (polysaccharide-K)",
              "type": "EXPERIMENTAL",
              "description": "Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.",
              "interventionNames": [
                "Biological: HER-2/neu Intracellular Domain Protein",
                "Other: Laboratory Biomarker Analysis",
                "Biological: Pertuzumab",
                "Biological: Polysaccharide-K",
                "Biological: Trastuzumab"
              ]
            }
          ],
          "interventions": [
            {
              "type": "BIOLOGICAL",
              "name": "HER-2/neu Intracellular Domain Protein",
              "description": "Given ID",
              "armGroupLabels": [
                "Arm I (placebo)",
                "Arm II (polysaccharide-K)"
              ],
              "otherNames": [
                "HER-2 ICD Peptide",
                "HER-2/neu ICD Protein",
                "HER2 ICD",
                "HER2 Intracellular Domain"
              ]
            },
            {
              "type": "OTHER",
              "name": "Laboratory Biomarker Analysis",
              "description": "Correlative studies",
              "armGroupLabels": [
                "Arm I (placebo)",
                "Arm II (polysaccharide-K)"
              ]
            },
            {
              "type": "BIOLOGICAL",
              "name": "Pertuzumab",
              "description": "Given per standard of care",
              "armGroupLabels": [
                "Arm I (placebo)",
                "Arm II (polysaccharide-K)"
              ],
              "otherNames": [
                "2C4",
                "2C4 Antibody",
                "MoAb 2C4",
                "Monoclonal Antibody 2C4",
                "Perjeta",
                "rhuMAb2C4",
                "RO4368451"
              ]
            },
            {
              "type": "OTHER",
              "name": "Placebo",
              "description": "Given PO",
              "armGroupLabels": [
                "Arm I (placebo)"
              ],
              "otherNames": [
                "placebo therapy",
                "PLCB",
                "sham therapy"
              ]
            },
            {
              "type": "BIOLOGICAL",
              "name": "Polysaccharide-K",
              "description": "Given PO",
              "armGroupLabels": [
                "Arm II (polysaccharide-K)"
              ],
              "otherNames": [
                "Glycoproteins",
                "Krestin",
                "KS-2",
                "PSK"
              ]
            },
            {
              "type": "BIOLOGICAL",
              "name": "Trastuzumab",
              "description": "Given per standard of care",
              "armGroupLabels": [
                "Arm I (placebo)",
                "Arm II (polysaccharide-K)"
              ],
              "otherNames": [
                "ABP 980",
                "Anti-c-ERB-2",
                "Anti-c-erbB2 Monoclonal Antibody",
                "Anti-ERB-2",
                "Anti-erbB-2",
                "Anti-erbB2 Monoclonal Antibody",
                "Anti-HER2/c-erbB2 Monoclonal Antibody",
                "Anti-p185-HER2",
                "c-erb-2 Monoclonal Antibody",
                "HER2 Monoclonal Antibody",
                "Herceptin",
                "Herceptin Biosimilar PF-05280014",
                "Herceptin Trastuzumab Biosimilar PF-05280014",
                "MoAb HER2",
                "Monoclonal Antibody c-erb-2",
                "Monoclonal Antibody HER2",
                "PF-05280014",
                "rhuMAb HER2",
                "RO0452317",
                "Trastuzumab Biosimilar ABP 980",
                "Trastuzumab Biosimilar PF-05280014"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Number of Patients With Grade 3 or Higher Toxicity Per Study Arm.",
              "description": "Evaluated using physical examinations and clinical labs by type and grade of toxicities noted during treatment, There were graded per Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events 4.0.",
              "timeFrame": "Up to 4 months"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Induction of Interferon (IFN)-Gamma Production and Cluster of Differentiation (CD)107a Expression in NK Cells, Via Flow Cytometry",
              "description": "Augmentation of NK cell activity is defined by a 2-fold increase (at time of maximal change) in NK cell IFN-gamma production and CD107a expression\n\nFor the results we used CD56 which is the accepted phenotypic marker for natural killer (NK) cells and CD16 which is a receptor on NK cells that facilitates antibody-dependent cellular cytotoxicity (ADCC). CD56dim are typically responsible for cytolytic activity and targets cell killing, whereas, CD56bright are the main source of cytokine production (i.e. IFN-gamma). CD56dim CD16bright NK cells represent at least 90% of all peripheral blood NK cells with a maximum of 10% as CD56bright NK cells\n\nWe compared the baseline expression of CD56brightCD16dim or CD56dimCD16bright (prior to start of study treatment) to the maximum expression of CD56brightCD16dim or CD56dimCD16bright at 1 of 4 timepoints after the start of the oral administration of study treatment (polysaccharide-K/placebo (either week 4, 8, 12 or 16).",
              "timeFrame": "Up to 16 weeks"
            }
          ],
          "otherOutcomes": [
            {
              "measure": "Change in Intermolecular Epitope Spreading Assessed by IFN-gamma Enzyme-linked Immunosorbent Spot Assay",
              "description": "IFN-\u03b3 ELISPOT assay will be used to evaluate T cell precursor frequency to specific breast tumor antigens. A positive immune response will be defined as a post-vaccination T cell precursor frequency \\>1:20,000 antigen-specific PBMCs. In patients with a baseline precursor frequency \\>1:20,000, a positive post-vaccination immune response will be defined as a 2-fold increase in antigen-specific PBMC. PBMC will be cryopreserved and subsequently be thawed at time of analysis.",
              "timeFrame": "Baseline to 12 months after completion of treatment"
            },
            {
              "measure": "Change in Pro-inflammatory Serum Cytokine and/or Chemokines Assessed by Luminex Analysis",
              "timeFrame": "Baseline to 24 hours after completion of treatment"
            },
            {
              "measure": "Change in Serum TGF-beta Levels Assessed by Enzyme-linked Immunosorbent Assay",
              "timeFrame": "Baseline to 12 months after completion of treatment"
            },
            {
              "measure": "OS",
              "timeFrame": "Up to 3 years"
            },
            {
              "measure": "PFS",
              "timeFrame": "Up to 3 years"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with stage IV HER2+ breast cancer treated to:\n\n  * No evidence of disease (NED), or\n  * Stable bone only disease after definitive therapy\n* HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in the primary tumor or metastasis; or documented gene amplification by fluorescent in situ hybridization (FISH) analysis; IHC =\\< 2+ must have HER2 gene amplification documented by FISH\n* Patients must continue HER2-targeted monoclonal antibody therapy dosing per standard of care through the entire study period (one year)\n\n  * HER2-targeted monoclonal antibody therapy is defined as either trastuzumab monotherapy, or trastuzumab and pertuzumab combination therapy administered per standard of care\n* Patients must be at least 21 days post cytotoxic chemotherapy prior to enrollment\n* Patients must be at least 28 days post immunosuppressants prior to enrollment\n* Patients must be at least 28 days from use of any mushroom supplements (examples: turkey tail, reishi, maitake, shiitake) and agree to withhold them for the entire study period (one year)\n* Patients on bisphosphonates and/or endocrine therapy are eligible\n* Patients who are having sex that could lead to pregnancy must agree to contraceptive use during the entire study period\n* Patients must have Zubrod performance status score of =\\< 2\n* Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have significant active concurrent medical illnesses precluding study treatment\n* White blood cell (WBC) \\>= 3000/mm\\^3\n* Hemoglobin (Hgb) \\>= 10 g/dl\n* Serum creatinine =\\< 2.0 mg/dl or creatinine clearance \\> 60 ml/min\n* Total bilirubin =\\< 1.5 mg/dl\n* Serum glutamic oxaloacetic transaminase (SGOT) =\\< 2.5 times the upper limit of normal\n* Patients must have adequate cardiac function as demonstrated by normal left ventricular ejection fraction (LVEF) \\>= the lower limit of normal for the facility on multi gated acquisition (MUGA) scan or echocardiogram (ECHO) within 3 months of enrollment\n\nExclusion Criteria:\n\n* Patients with any of the following cardiac conditions:\n\n  * Restrictive cardiomyopathy\n  * Unstable angina within 6 months prior to enrollment\n  * New York Heart Association functional class III-IV heart failure\n  * Symptomatic pericardial effusion\n* Patients with any contraindication to receiving rhu granulocyte macrophage colony stimulating factor (rhuGM-CSF) based products\n* Patients with any clinically significant autoimmune disease requiring active treatment\n* Patients receiving any concurrent immunosuppressants\n* Patients who are pregnant or breast-feeding\n* Patients who are simultaneously enrolled in other treatment studies\n* Patients who have received a previous HER2 breast cancer vaccine\n* Known hypersensitivity reaction to mushroom products",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Lupe Salazar",
              "affiliation": "Fred Hutch/University of Washington Cancer Consortium",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Fred Hutch/University of Washington Cancer Consortium",
              "city": "Seattle",
              "state": "Washington",
              "zip": "98109",
              "country": "United States",
              "geoPoint": {
                "lat": 47.60621,
                "lon": -122.33207
              }
            }
          ]
        }
      },
      "resultsSection": {
        "participantFlowModule": {
          "groups": [
            {
              "id": "FG000",
              "title": "Arm I (Placebo)",
              "description": "Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPlacebo: Given PO\n\nTrastuzumab: Given per standard of care"
            },
            {
              "id": "FG001",
              "title": "Arm II (Polysaccharide-K)",
              "description": "Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPolysaccharide-K: Given PO\n\nTrastuzumab: Given per standard of care"
            }
          ],
          "periods": [
            {
              "title": "Overall Study",
              "milestones": [
                {
                  "type": "STARTED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "16"
                    },
                    {
                      "groupId": "FG001",
                      "numSubjects": "15"
                    }
                  ]
                },
                {
                  "type": "COMPLETED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "15"
                    },
                    {
                      "groupId": "FG001",
                      "numSubjects": "14"
                    }
                  ]
                },
                {
                  "type": "NOT COMPLETED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "1"
                    },
                    {
                      "groupId": "FG001",
                      "numSubjects": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        "baselineCharacteristicsModule": {
          "groups": [
            {
              "id": "BG000",
              "title": "Arm I (Placebo)",
              "description": "Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPlacebo: Given PO\n\nTrastuzumab: Given per standard of care"
            },
            {
              "id": "BG001",
              "title": "Arm II (Polysaccharide-K)",
              "description": "Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPolysaccharide-K: Given PO\n\nTrastuzumab: Given per standard of care"
            },
            {
              "id": "BG002",
              "title": "Total",
              "description": "Total of all reporting groups"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "BG000",
                  "value": "16"
                },
                {
                  "groupId": "BG001",
                  "value": "15"
                },
                {
                  "groupId": "BG002",
                  "value": "31"
                }
              ]
            }
          ],
          "measures": [
            {
              "title": "Age, Continuous",
              "paramType": "MEDIAN",
              "dispersionType": "FULL_RANGE",
              "unitOfMeasure": "years",
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "52",
                          "lowerLimit": "36",
                          "upperLimit": "62"
                        },
                        {
                          "groupId": "BG001",
                          "value": "59",
                          "lowerLimit": "33",
                          "upperLimit": "75"
                        },
                        {
                          "groupId": "BG002",
                          "value": "52",
                          "lowerLimit": "33",
                          "upperLimit": "75"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Sex: Female, Male",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "Female",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "16"
                        },
                        {
                          "groupId": "BG001",
                          "value": "15"
                        },
                        {
                          "groupId": "BG002",
                          "value": "31"
                        }
                      ]
                    },
                    {
                      "title": "Male",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ethnicity (NIH/OMB)",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "Hispanic or Latino",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Not Hispanic or Latino",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "16"
                        },
                        {
                          "groupId": "BG001",
                          "value": "15"
                        },
                        {
                          "groupId": "BG002",
                          "value": "31"
                        }
                      ]
                    },
                    {
                      "title": "Unknown or Not Reported",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Race (NIH/OMB)",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "American Indian or Alaska Native",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Asian",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "2"
                        },
                        {
                          "groupId": "BG001",
                          "value": "2"
                        },
                        {
                          "groupId": "BG002",
                          "value": "4"
                        }
                      ]
                    },
                    {
                      "title": "Native Hawaiian or Other Pacific Islander",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Black or African American",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "White",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "14"
                        },
                        {
                          "groupId": "BG001",
                          "value": "13"
                        },
                        {
                          "groupId": "BG002",
                          "value": "27"
                        }
                      ]
                    },
                    {
                      "title": "More than one race",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Unknown or Not Reported",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Region of Enrollment",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "title": "United States",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "16"
                        },
                        {
                          "groupId": "BG001",
                          "value": "13"
                        },
                        {
                          "groupId": "BG002",
                          "value": "29"
                        }
                      ]
                    }
                  ]
                },
                {
                  "title": "Italy",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "1"
                        },
                        {
                          "groupId": "BG002",
                          "value": "1"
                        }
                      ]
                    }
                  ]
                },
                {
                  "title": "Canada",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        },
                        {
                          "groupId": "BG001",
                          "value": "1"
                        },
                        {
                          "groupId": "BG002",
                          "value": "1"
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        "outcomeMeasuresModule": {
          "outcomeMeasures": [
            {
              "type": "PRIMARY",
              "title": "Number of Patients With Grade 3 or Higher Toxicity Per Study Arm.",
              "description": "Evaluated using physical examinations and clinical labs by type and grade of toxicities noted during treatment, There were graded per Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events 4.0.",
              "populationDescription": "Only 1 patient of the 2 patients listed below had a possibly related event of vomiting.",
              "reportingStatus": "POSTED",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "timeFrame": "Up to 4 months",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Arm I (Placebo)",
                  "description": "Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPlacebo: Given PO\n\nTrastuzumab: Given per standard of care"
                },
                {
                  "id": "OG001",
                  "title": "Arm II (Polysaccharide-K)",
                  "description": "Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPolysaccharide-K: Given PO\n\nTrastuzumab: Given per standard of care"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "16"
                    },
                    {
                      "groupId": "OG001",
                      "value": "15"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "2"
                        },
                        {
                          "groupId": "OG001",
                          "value": "0"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Induction of Interferon (IFN)-Gamma Production and Cluster of Differentiation (CD)107a Expression in NK Cells, Via Flow Cytometry",
              "description": "Augmentation of NK cell activity is defined by a 2-fold increase (at time of maximal change) in NK cell IFN-gamma production and CD107a expression\n\nFor the results we used CD56 which is the accepted phenotypic marker for natural killer (NK) cells and CD16 which is a receptor on NK cells that facilitates antibody-dependent cellular cytotoxicity (ADCC). CD56dim are typically responsible for cytolytic activity and targets cell killing, whereas, CD56bright are the main source of cytokine production (i.e. IFN-gamma). CD56dim CD16bright NK cells represent at least 90% of all peripheral blood NK cells with a maximum of 10% as CD56bright NK cells\n\nWe compared the baseline expression of CD56brightCD16dim or CD56dimCD16bright (prior to start of study treatment) to the maximum expression of CD56brightCD16dim or CD56dimCD16bright at 1 of 4 timepoints after the start of the oral administration of study treatment (polysaccharide-K/placebo (either week 4, 8, 12 or 16).",
              "populationDescription": "Only 9/15 patients were evaluable for this analysis in Arm 1. Only 13/14 patients we evaluable for this analysis in Arm 2.",
              "reportingStatus": "POSTED",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "timeFrame": "Up to 16 weeks",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Arm I (Placebo) - CD56dim CD16bright",
                  "description": "Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPlacebo: Given PO\n\nTrastuzumab: Given per standard of care"
                },
                {
                  "id": "OG001",
                  "title": "Arm II (Polysaccharide-K) - CD56dim CD16bright",
                  "description": "Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPolysaccharide-K: Given PO\n\nTrastuzumab: Given per standard of care"
                },
                {
                  "id": "OG002",
                  "title": "Arm I (Placebo) - CD56bright CD16dim",
                  "description": "Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPlacebo: Given PO\n\nTrastuzumab: Given per standard of care"
                },
                {
                  "id": "OG003",
                  "title": "Arm II (Polysaccharide-K) - CD56bright CD16dim",
                  "description": "Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPolysaccharide-K: Given PO\n\nTrastuzumab: Given per standard of care"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "13"
                    },
                    {
                      "groupId": "OG002",
                      "value": "9"
                    },
                    {
                      "groupId": "OG003",
                      "value": "13"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "title": "INF gamma+",
                  "categories": [
                    {
                      "title": ">=2 fold increase",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "4"
                        },
                        {
                          "groupId": "OG001",
                          "value": "9"
                        },
                        {
                          "groupId": "OG002",
                          "value": "4"
                        },
                        {
                          "groupId": "OG003",
                          "value": "7"
                        }
                      ]
                    },
                    {
                      "title": "<2 fold increase",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "5"
                        },
                        {
                          "groupId": "OG001",
                          "value": "4"
                        },
                        {
                          "groupId": "OG002",
                          "value": "5"
                        },
                        {
                          "groupId": "OG003",
                          "value": "6"
                        }
                      ]
                    }
                  ]
                },
                {
                  "title": "CD107+",
                  "categories": [
                    {
                      "title": ">=2 fold increase",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "3"
                        },
                        {
                          "groupId": "OG001",
                          "value": "8"
                        },
                        {
                          "groupId": "OG002",
                          "value": "3"
                        },
                        {
                          "groupId": "OG003",
                          "value": "6"
                        }
                      ]
                    },
                    {
                      "title": "<2 fold increase",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "6"
                        },
                        {
                          "groupId": "OG001",
                          "value": "5"
                        },
                        {
                          "groupId": "OG002",
                          "value": "6"
                        },
                        {
                          "groupId": "OG003",
                          "value": "7"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "OTHER_PRE_SPECIFIED",
              "title": "Change in Intermolecular Epitope Spreading Assessed by IFN-gamma Enzyme-linked Immunosorbent Spot Assay",
              "description": "IFN-\u03b3 ELISPOT assay will be used to evaluate T cell precursor frequency to specific breast tumor antigens. A positive immune response will be defined as a post-vaccination T cell precursor frequency \\>1:20,000 antigen-specific PBMCs. In patients with a baseline precursor frequency \\>1:20,000, a positive post-vaccination immune response will be defined as a 2-fold increase in antigen-specific PBMC. PBMC will be cryopreserved and subsequently be thawed at time of analysis.",
              "reportingStatus": "NOT_POSTED",
              "timeFrame": "Baseline to 12 months after completion of treatment",
              "denomUnitsSelected": "Participants"
            },
            {
              "type": "OTHER_PRE_SPECIFIED",
              "title": "Change in Pro-inflammatory Serum Cytokine and/or Chemokines Assessed by Luminex Analysis",
              "reportingStatus": "NOT_POSTED",
              "timeFrame": "Baseline to 24 hours after completion of treatment",
              "denomUnitsSelected": "Participants"
            },
            {
              "type": "OTHER_PRE_SPECIFIED",
              "title": "Change in Serum TGF-beta Levels Assessed by Enzyme-linked Immunosorbent Assay",
              "reportingStatus": "NOT_POSTED",
              "timeFrame": "Baseline to 12 months after completion of treatment",
              "denomUnitsSelected": "Participants"
            },
            {
              "type": "OTHER_PRE_SPECIFIED",
              "title": "OS",
              "reportingStatus": "NOT_POSTED",
              "timeFrame": "Up to 3 years",
              "denomUnitsSelected": "Participants"
            },
            {
              "type": "OTHER_PRE_SPECIFIED",
              "title": "PFS",
              "reportingStatus": "NOT_POSTED",
              "timeFrame": "Up to 3 years",
              "denomUnitsSelected": "Participants"
            }
          ]
        },
        "adverseEventsModule": {
          "frequencyThreshold": "0",
          "timeFrame": "Clinical and/or chemical parameters for all study patients will be evaluated for potential toxicity at baseline, before each vaccine, and 1 month after the third vaccine (total of 4 months evaluation).",
          "description": "Toxicity grading will be evaluated per CTEP CTCAE 4.0 and monitoring of AEs will be done per FDA and NCI guidelines. AEs will be tabulated per CTCAE 4.0 system organ class and descriptive statistics will be used to summarize toxicity profiles for the PSK and placebo groups.",
          "eventGroups": [
            {
              "id": "EG000",
              "title": "Arm I (Placebo)",
              "description": "Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPlacebo: Given PO\n\nTrastuzumab: Given per standard of care",
              "deathsNumAffected": 1,
              "deathsNumAtRisk": 16,
              "seriousNumAffected": 0,
              "seriousNumAtRisk": 16,
              "otherNumAffected": 16,
              "otherNumAtRisk": 16
            },
            {
              "id": "EG001",
              "title": "Arm II (Polysaccharide-K)",
              "description": "Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.\n\nHER-2/neu Intracellular Domain Protein: Given ID\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPertuzumab: Given per standard of care\n\nPolysaccharide-K: Given PO\n\nTrastuzumab: Given per standard of care",
              "deathsNumAffected": 2,
              "deathsNumAtRisk": 15,
              "seriousNumAffected": 0,
              "seriousNumAtRisk": 15,
              "otherNumAffected": 15,
              "otherNumAtRisk": 15
            }
          ],
          "otherEvents": [
            {
              "term": "Lymphocyte count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "4/7 events reported were related to placebo arm 4/5 events reported were related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 7,
                  "numAffected": 6,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 4,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "White blood cell decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "4/4 events reported were related to the placebo arm 1/3 events reported were related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 3,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Platelet count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 5,
                  "numAffected": 4,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Neutrophil count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm 1/1 events reported was related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Alanine aminotransferase increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Cough",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dyspnea",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Other - rhinorrhea",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Anemia",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/4 events reported were related to placebo arm 1/6 events reported were related to treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 7,
                  "numAffected": 6,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Arthralgia",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Pain in extremity",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Sinusitis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Upper respiratory infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Other - pneumonia",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Cognitive disturbance",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dizziness",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Headache",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm 6/9 events reported were related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 9,
                  "numAffected": 7,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Paresthesia",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dysesthesia",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Diarrhea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/4 events reported were related to placebo arm 7/8 events reported were related to treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 8,
                  "numAffected": 6,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Nausea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "3/5 events reported were related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 5,
                  "numAffected": 3,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Vomiting",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "2/4 events reported were related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 4,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Constipation",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Bloating",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Abdominal pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/2 events reported were related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Other - minor acid reflux after drinking tea for half hour or so",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dry mouth",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Flatulence",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/3 events reported were related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Rash acneiform",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Rash maculo-papular",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Other - acne/rash",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Fatigue",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "2/2 events reported were related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 6,
                  "numAffected": 5,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Flu like symptoms",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "5/8 events reported were related to placebo arm 12/12 events reported were related to treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 8,
                  "numAffected": 7,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 12,
                  "numAffected": 7,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Non-cardiac chest pain",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Pain",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 reported events was related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Injection site reaction",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "29/29 events reported were related to placebo arm 25/26 events reported were related to treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 29,
                  "numAffected": 14,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 26,
                  "numAffected": 13,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Gait disturbance",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hot flashes",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm 1/2 events reported were related to treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Other - head sweats-daily",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypocalcemia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 reported events was related to treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 5,
                  "numAffected": 5,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypokalemia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hyponatremia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/2 events reported were related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypoalbuminemia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "2/3 events reported were related to treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Other - dysuria",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Other - engorged breast",
              "organSystem": "Reproductive system and breast disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Allergic reaction",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Other - hyperactive-increase senstivity of allergens-food, pollen, bug bite",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to placebo arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Blood bilirubin increase",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Post nasal drip",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Myalgia",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Right knee pain increased",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Left lip cold sores (Herpes)",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Paronychia",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Palpitations",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Peripheral sensory neuropathy",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hematochezia - 2 episodes",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Gastroesophageal reflux disease",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "3/3 events reported were related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dyspepsia",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Alopecia",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Umbilical follicitis",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Scalp skin nodule",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Edema limbs",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Infusion related reactions",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/1 events reported was related to treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hyperglycemia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "1/2 events reported were related to the treatment arm",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Cystitis - UTI",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "CTCAE (4.0)",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 16
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            }
          ]
        },
        "moreInfoModule": {
          "certainAgreement": {
            "piSponsorEmployee": false,
            "restrictiveAgreement": false
          },
          "pointOfContact": {
            "title": "Director of Clinical Operations",
            "organization": "University of Washington",
            "email": "childj@u.washington.edu",
            "phone": "2066162305"
          }
        }
      },
      "documentSection": {
        "largeDocumentModule": {
          "largeDocs": [
            {
              "typeAbbrev": "Prot_SAP",
              "hasProtocol": true,
              "hasSap": true,
              "hasIcf": false,
              "label": "Study Protocol and Statistical Analysis Plan",
              "date": "2021-09-03",
              "uploadDate": "2023-01-06T12:54",
              "filename": "Prot_SAP_000.pdf",
              "size": 1689015
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2025-09-08"
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D001943",
              "term": "Breast Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D009369",
              "term": "Neoplasms"
            },
            {
              "id": "D001941",
              "term": "Breast Diseases"
            },
            {
              "id": "D012871",
              "term": "Skin Diseases"
            },
            {
              "id": "D017437",
              "term": "Skin and Connective Tissue Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "C485206",
              "term": "pertuzumab"
            },
            {
              "id": "C481039",
              "term": "2C4 antibody"
            },
            {
              "id": "D058110",
              "term": "Counterfeit Drugs"
            },
            {
              "id": "C010770",
              "term": "polysaccharide-K"
            },
            {
              "id": "D006023",
              "term": "Glycoproteins"
            },
            {
              "id": "D000068878",
              "term": "Trastuzumab"
            },
            {
              "id": "C000598430",
              "term": "PF-05280014"
            }
          ],
          "ancestors": [
            {
              "id": "D000078742",
              "term": "Substandard Drugs"
            },
            {
              "id": "D004364",
              "term": "Pharmaceutical Preparations"
            },
            {
              "id": "D006001",
              "term": "Glycoconjugates"
            },
            {
              "id": "D002241",
              "term": "Carbohydrates"
            },
            {
              "id": "D011506",
              "term": "Proteins"
            },
            {
              "id": "D000602",
              "term": "Amino Acids, Peptides, and Proteins"
            },
            {
              "id": "D061067",
              "term": "Antibodies, Monoclonal, Humanized"
            },
            {
              "id": "D000911",
              "term": "Antibodies, Monoclonal"
            },
            {
              "id": "D000906",
              "term": "Antibodies"
            },
            {
              "id": "D007136",
              "term": "Immunoglobulins"
            },
            {
              "id": "D007162",
              "term": "Immunoproteins"
            },
            {
              "id": "D001798",
              "term": "Blood Proteins"
            },
            {
              "id": "D012712",
              "term": "Serum Globulins"
            },
            {
              "id": "D005916",
              "term": "Globulins"
            }
          ]
        }
      },
      "hasResults": true,
      "McodeResults": {
        "extracted_entities": [],
        "mcode_mappings": [
          {
            "resourceType": "Observation",
            "mcode_element": "Biomarker",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "biomarker",
              "display": "Biomarker"
            },
            "value": "Positive",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER2/Neu Positive",
            "mapping_rationale": "Explicitly stated biomarker status in the text.",
            "id": "f09f3e4b-e1dc-426f-b330-6f504a63f1f3"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Recurrent Breast Carcinoma",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Recurrent Breast Carcinoma",
            "mapping_rationale": "Explicitly stated cancer diagnosis in the text.",
            "id": "e62d12fd-8871-4454-a4cb-fcd6b12a30b8"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMClinicalStageGroup",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmclinicalstagegroup",
              "display": "TNMClinicalStageGroup"
            },
            "value": "IV",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Stage IV Breast Cancer",
            "mapping_rationale": "Explicitly stated cancer staging in the text.",
            "id": "9eab9477-bfd2-46a3-a51e-30266784682f"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Stage IV HER2+ breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Patients with stage IV HER2+ breast cancer treated to: No evidence of disease (NED), or Stable bone only disease after definitive therapy",
            "mapping_rationale": "Explicitly stated diagnosis in inclusion criteria",
            "id": "e83241f0-3ee1-43ac-8c69-63c07ee349f3"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "GenomicVariant",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "genomicvariant",
              "display": "GenomicVariant"
            },
            "value": "HER2 positive by IHC or FISH",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in the primary tumor or metastasis; or documented gene amplification by fluorescent in situ hybridization (FISH) analysis",
            "mapping_rationale": "Explicit criteria for HER2 status in inclusion criteria",
            "id": "3f3be8eb-5bac-4cb0-b9c6-591c0abd4fa0"
          },
          {
            "resourceType": "MedicationStatement",
            "mcode_element": "CancerRelatedMedication",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancerrelatedmedication",
              "display": "CancerRelatedMedication"
            },
            "value": "trastuzumab monotherapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER2-targeted monoclonal antibody therapy is defined as either trastuzumab monotherapy, or trastuzumab and pertuzumab combination therapy administered per standard of care",
            "mapping_rationale": "Explicit definition of treatment including trastuzumab",
            "id": "c943dd29-540c-4cac-bb58-c56b7f73be4e"
          },
          {
            "resourceType": "MedicationStatement",
            "mcode_element": "CancerRelatedMedication",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancerrelatedmedication",
              "display": "CancerRelatedMedication"
            },
            "value": "pertuzumab in combination therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER2-targeted monoclonal antibody therapy is defined as either trastuzumab monotherapy, or trastuzumab and pertuzumab combination therapy administered per standard of care",
            "mapping_rationale": "Explicit mention of pertuzumab in treatment definition",
            "id": "e2b8c0ef-103f-4110-8cd3-38d3d06d5e17"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Age",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "age",
              "display": "Age"
            },
            "value": ">=18",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Exclusion Criteria: * Known hypersensitivity reaction to mushroom products minimumAge: 18 Years healthyVolunteers: False",
            "mapping_rationale": "Explicit minimum age requirement stated at the end of the text",
            "id": "0d8d8826-cb48-4a16-9158-03753f23e467"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "PerformanceStatus",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "performancestatus",
              "display": "PerformanceStatus"
            },
            "value": "<=2",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Inclusion Criteria: * Patients must have Zubrod performance status score of =< 2",
            "mapping_rationale": "Explicit performance status criteria in inclusion criteria",
            "id": "74ac49d3-6a4e-45fd-a001-7b601e828739"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "HER2 positive breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
            "mapping_rationale": "Explicitly stated cancer diagnosis in source text",
            "id": "50cb8099-f336-4756-a0eb-fa8a21d30042"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "IV",
            "mapping_confidence": 1.0,
            "source_text_fragment": "patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
            "mapping_rationale": "Explicitly stated cancer stage in source text",
            "id": "a89410d5-f9e8-42ac-a73e-4f6ecf836cb3"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Trastuzumab",
            "mapping_confidence": 1.0,
            "source_text_fragment": "trastuzumab (or trastuzumab and pertuzumab) per standard of care",
            "mapping_rationale": "Explicitly stated medication in treatment arm",
            "id": "5b8bba41-43ef-4c81-a3f1-d6ea6d58833c"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Pertuzumab",
            "mapping_confidence": 1.0,
            "source_text_fragment": "trastuzumab (or trastuzumab and pertuzumab) per standard of care",
            "mapping_rationale": "Explicitly stated medication in treatment arm",
            "id": "dab762e9-81c2-4d0f-8005-a1413395809a"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Polysaccharide-K",
            "mapping_confidence": 0.8,
            "source_text_fragment": "ARM II: Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months",
            "mapping_rationale": "Explicitly stated medication, code is approximate as it is a general immunomodulator",
            "id": "762fa1e8-1e7e-4901-8a01-13cde505979c"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "HER2 ICD peptide-based vaccine",
            "mapping_confidence": 0.8,
            "source_text_fragment": "HER2 ICD peptide-based vaccine intradermally (ID) once monthly for 3 months",
            "mapping_rationale": "Explicitly stated treatment, code is general as it is a specific vaccine type",
            "id": "56a49e3e-37e9-4d36-9fa9-fd483b8f2d5c"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER2 Positive Breast Cancer",
            "mapping_rationale": "Explicitly stated in the clinical text",
            "id": "ed72f36a-05d6-41df-8a06-6c9f28a11928"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "Stage IV",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Stage IV",
            "mapping_rationale": "Explicitly stated in the clinical text",
            "id": "c9700745-d588-455b-a5b0-7533c02c116e"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerBiomarker",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancerbiomarker",
              "display": "CancerBiomarker"
            },
            "value": "Positive",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER2 Positive",
            "mapping_rationale": "Explicitly stated in the clinical text",
            "id": "66219807-8c00-4dbb-ac73-0d58002e31c1"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "HER2-Targeted Monoclonal Antibody Therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Receiving HER2-Targeted Monoclonal Antibody Therapy",
            "mapping_rationale": "Explicitly stated in the clinical text",
            "id": "fd272b1d-eb0c-4ef8-9ee6-7329133f897b"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Vaccine Therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Vaccine Therapy",
            "mapping_rationale": "Explicitly stated in the clinical text",
            "id": "3069a8e1-e4e4-4910-8ebd-473ca790fc17"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Polysaccharide-K",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Polysaccharide-K",
            "mapping_rationale": "Explicitly stated in the clinical text",
            "id": "de1aa35b-30da-4c66-b505-c8725ce80ff6"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "HER2 ICD Peptide-Based Vaccine",
            "mapping_confidence": 1.0,
            "source_text_fragment": "a HER2 ICD Peptide-Based Vaccine",
            "mapping_rationale": "Explicitly stated in the clinical text",
            "id": "786eecac-6e5e-48d1-9423-854c13529421"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Polysaccharide Krestin (PSK\u00ae)",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Polysaccharide Krestin (PSK\u00ae)",
            "mapping_rationale": "Explicitly stated in the clinical text",
            "id": "d8c8d1ee-2f3d-4b16-b7cc-a4f06c9b4df2"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Given per standard of care",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Trastuzumab: Given per standard of care",
            "mapping_rationale": "Explicit medication administration statement.",
            "id": "cc7d3d9d-b5d8-431b-9053-17fdd42f0d38"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Given per standard of care",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Pertuzumab: Given per standard of care",
            "mapping_rationale": "Explicit medication administration statement.",
            "id": "92354515-544c-4d17-a8b8-c5689286484a"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Given PO",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Placebo: Given PO",
            "mapping_rationale": "Explicit medication administration statement.",
            "id": "ad7622fa-9c8c-4bfd-aae5-d2e288f7b512"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Given ID",
            "mapping_confidence": 0.8,
            "source_text_fragment": "HER-2/neu Intracellular Domain Protein: Given ID",
            "mapping_rationale": "Medication mentioned but SNOMED code is general for cancer vaccine.",
            "id": "09df7012-b81b-408d-9ff9-cc95dd79456b"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "DemographicObservation",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "demographicobservation",
              "display": "DemographicObservation"
            },
            "value": "Median 52 years (range 33-75)",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"value\": \"52\", \"lowerLimit\": \"33\", \"upperLimit\": \"75\" for group BG002 in Age, Continuous measure",
            "mapping_rationale": "Explicit age data for total group.",
            "id": "decd32d6-7d53-4f54-a00a-cf240bc7e55d"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "DemographicObservation",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "demographicobservation",
              "display": "DemographicObservation"
            },
            "value": "Female: 31, Male: 0",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"value\": \"31\" for Female and \"value\": \"0\" for Male in group BG002 of Sex measure",
            "mapping_rationale": "Explicit sex distribution data for total group.",
            "id": "b8d59c57-ecc7-4093-8fda-933649007d69"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "DemographicObservation",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "demographicobservation",
              "display": "DemographicObservation"
            },
            "value": "Not Hispanic or Latino: 31",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"title\": \"Not Hispanic or Latino\", \"measurements\": [{\"groupId\": \"BG002\", \"value\": \"31\"}]",
            "mapping_rationale": "Explicit ethnicity data for total group.",
            "id": "76434992-0d09-4d82-aa7f-9b0c97ba943e"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "DemographicObservation",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "demographicobservation",
              "display": "DemographicObservation"
            },
            "value": "White: 27, Asian: 4",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"title\": \"White\", \"measurements\": [{\"groupId\": \"BG002\", \"value\": \"27\"}] and \"title\": \"Asian\", \"measurements\": [{\"groupId\": \"BG002\", \"value\": \"4\"}]",
            "mapping_rationale": "Explicit race data for total group.",
            "id": "a5fe248a-b8ba-4ff0-a4e5-372605cbf63e"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"IFN-\u03b3 ELISPOT assay will be used to evaluate T cell precursor frequency to specific breast tumor antigens.\"",
            "mapping_rationale": "Explicit mention of 'breast tumor antigens' indicates the cancer type.",
            "id": "f9e2426c-3e66-4a16-b9ac-f6ec4eb47561"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "HER2 ICD peptide-based vaccine",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\"",
            "mapping_rationale": "Explicitly stated medication in the treatment regimen.",
            "id": "0a911cb4-672b-4a66-bd1e-8dfe75639bf2"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Trastuzumab",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\"",
            "mapping_rationale": "Explicitly stated medication in the treatment regimen.",
            "id": "598b2c4d-5f72-43d8-90a1-eb51adade929"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Pertuzumab",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\"",
            "mapping_rationale": "Explicitly stated medication option in the treatment regimen.",
            "id": "c7384c2a-b988-404b-9d04-efdd197726bb"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Placebo",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.\"",
            "mapping_rationale": "Explicitly stated control substance in the treatment regimen.",
            "id": "513b7b99-b623-4974-83e4-9e75f8ecd5bc"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Polysaccharide-K",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.\"",
            "mapping_rationale": "Explicitly stated medication in the treatment regimen for Arm II.",
            "id": "9ae6336e-f337-4964-8e36-dbb74a2c5392"
          }
        ],
        "source_references": [],
        "validation": {
          "valid": true,
          "errors": [],
          "warnings": [],
          "compliance_score": 1.0
        },
        "metadata": {
          "pipeline_version": "Mcode_pipeline_v1",
          "engine_type": "LLM",
          "entities_count": 0,
          "mapped_count": 37,
          "compliance_score": 1.0,
          "token_usage": {
            "prompt_tokens": 3247,
            "completion_tokens": 6376,
            "total_tokens": 9623
          },
          "aggregate_token_usage": {
            "prompt_tokens": 0,
            "completion_tokens": 0,
            "total_tokens": 0,
            "model_name": "",
            "provider_name": ""
          }
        },
        "error": null
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01026116",
          "orgStudyIdInfo": {
            "id": "SHBCC09007"
          },
          "organization": {
            "fullName": "Fudan University",
            "class": "OTHER"
          },
          "briefTitle": "A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old",
          "officialTitle": "Comparing EC-wP Versus EP-wP as Adjuvant Therapy for Breast Cancer Patients Less Than 40 Years Old"
        },
        "statusModule": {
          "statusVerifiedDate": "2020-05",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2009-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-12-23",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2009-12-03",
          "studyFirstSubmitQcDate": "2009-12-03",
          "studyFirstPostDateStruct": {
            "date": "2009-12-04",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2020-05-09",
          "lastUpdatePostDateStruct": {
            "date": "2020-05-12",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "Zhimin Shao",
            "investigatorTitle": "Director of Breast Surgery Department",
            "investigatorAffiliation": "Fudan University"
          },
          "leadSponsor": {
            "name": "Fudan University",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history. The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients."
        },
        "conditionsModule": {
          "conditions": [
            "Breast Neoplasms"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE3"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "PARALLEL",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 521,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "EC-wP",
              "type": "ACTIVE_COMPARATOR",
              "description": "epirubicin/cyclophosphamide followed weekly paclitaxel",
              "interventionNames": [
                "Drug: Epirubicin",
                "Drug: Cyclophosphamide",
                "Drug: Paclitaxel"
              ]
            },
            {
              "label": "EP-wP",
              "type": "EXPERIMENTAL",
              "description": "epirubicin/paclitaxel followed by weekly paclitaxel",
              "interventionNames": [
                "Drug: Epirubicin",
                "Drug: Cyclophosphamide",
                "Drug: Paclitaxel"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Epirubicin",
              "description": "75 mg/m2 every-3-week for four cycles",
              "armGroupLabels": [
                "EC-wP",
                "EP-wP"
              ]
            },
            {
              "type": "DRUG",
              "name": "Cyclophosphamide",
              "description": "600 mg/m2 every-3-week for four cycles",
              "armGroupLabels": [
                "EC-wP",
                "EP-wP"
              ]
            },
            {
              "type": "DRUG",
              "name": "Paclitaxel",
              "description": "175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks",
              "armGroupLabels": [
                "EC-wP",
                "EP-wP"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "disease-free survival",
              "timeFrame": "every one year"
            },
            {
              "measure": "menstrual resumption rate",
              "description": "Resumption of menses was defined as at least 2 consecutive menstruations, or at least 1 menstruation with a confirmed premenopausal level of FSH and estradiol after chemotherapy",
              "timeFrame": "12 months after chemotherapy"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "overall survival",
              "timeFrame": "every one year"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients, age 18\\~40\n* Unilateral, operable, histologically confirmed adenocarcinoma of the breast\n* Stage I-III\n* Primary surgery with clear margins plus axillary dissection\n* Able to start protocol Rx within 8 weeks of surgery\n* Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer: the immunohistochemical cut-off for ER positive status was\n\n  1% or more staining in nuclei\n* HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test by chemotherapy\n* pathologically confirmed regional node-positive disease, or node-negative disease with high-risk factors (primary tumor diameter \\>10 mm when histological grade III, or tumor diameter \\>20 mm when histological grade II)\n* ECOG performance status 0-1\n* Adequate cardiac, renal, hepatic and hematologic function\n\nExclusion Criteria:\n\n* Metastatic disease\n* Bilateral breast cancer (synchronous or metachronous)\n* Prior radiation therapy, hormonal therapy and chemotherapy for breast cancer\n* Previous cancer (except treated basal cell and squamous cell carcinoma of the skin or cancer of the uterine cervix)\n* HER-2 positive (IHC 3+ OR FISH+) and or triple-negative breast cancer\n* Documented history of cardiac disease contradiction anthracyclines\n* Concurrent serious illness\n* Peripheral neuropathy of CTC grade\\>1\n* History of hypersensitivity to drugs formulated in Cremophor EL polyoxyethylated castor oil), the vehicle used for commercial paclitaxel formulations\n* Pregnancy or lactation",
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "40 Years",
          "stdAges": [
            "ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Zhimin Shao",
              "affiliation": "Cancer Hospital, Fudan University",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Department of Breast Surgery, Cancer Hospital, Fudan University",
              "city": "Shanghai",
              "zip": "200032",
              "country": "China",
              "geoPoint": {
                "lat": 31.22222,
                "lon": 121.45806
              }
            }
          ]
        },
        "referencesModule": {
          "references": [
            {
              "pmid": "33822134",
              "type": "DERIVED",
              "citation": "Yu KD, Ge JY, Liu XY, Mo M, He M, Shao ZM; SPECTRUM Investigators. Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial. J Natl Cancer Inst. 2021 Oct 1;113(10):1352-1359. doi: 10.1093/jnci/djab065."
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2025-09-08"
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D001943",
              "term": "Breast Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D009369",
              "term": "Neoplasms"
            },
            {
              "id": "D001941",
              "term": "Breast Diseases"
            },
            {
              "id": "D012871",
              "term": "Skin Diseases"
            },
            {
              "id": "D017437",
              "term": "Skin and Connective Tissue Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D015251",
              "term": "Epirubicin"
            },
            {
              "id": "D003520",
              "term": "Cyclophosphamide"
            },
            {
              "id": "D017239",
              "term": "Paclitaxel"
            }
          ],
          "ancestors": [
            {
              "id": "D004317",
              "term": "Doxorubicin"
            },
            {
              "id": "D003630",
              "term": "Daunorubicin"
            },
            {
              "id": "D018943",
              "term": "Anthracyclines"
            },
            {
              "id": "D009279",
              "term": "Naphthacenes"
            },
            {
              "id": "D011084",
              "term": "Polycyclic Aromatic Hydrocarbons"
            },
            {
              "id": "D006841",
              "term": "Hydrocarbons, Aromatic"
            },
            {
              "id": "D006844",
              "term": "Hydrocarbons, Cyclic"
            },
            {
              "id": "D006838",
              "term": "Hydrocarbons"
            },
            {
              "id": "D009930",
              "term": "Organic Chemicals"
            },
            {
              "id": "D011083",
              "term": "Polycyclic Compounds"
            },
            {
              "id": "D000617",
              "term": "Aminoglycosides"
            },
            {
              "id": "D006027",
              "term": "Glycosides"
            },
            {
              "id": "D002241",
              "term": "Carbohydrates"
            },
            {
              "id": "D010752",
              "term": "Phosphoramide Mustards"
            },
            {
              "id": "D009588",
              "term": "Nitrogen Mustard Compounds"
            },
            {
              "id": "D009150",
              "term": "Mustard Compounds"
            },
            {
              "id": "D006846",
              "term": "Hydrocarbons, Halogenated"
            },
            {
              "id": "D063088",
              "term": "Phosphoramides"
            },
            {
              "id": "D009943",
              "term": "Organophosphorus Compounds"
            },
            {
              "id": "D043823",
              "term": "Taxoids"
            },
            {
              "id": "D043822",
              "term": "Cyclodecanes"
            },
            {
              "id": "D003516",
              "term": "Cycloparaffins"
            },
            {
              "id": "D006840",
              "term": "Hydrocarbons, Alicyclic"
            },
            {
              "id": "D004224",
              "term": "Diterpenes"
            },
            {
              "id": "D013729",
              "term": "Terpenes"
            }
          ]
        }
      },
      "hasResults": false,
      "McodeResults": {
        "extracted_entities": [],
        "mcode_mappings": [
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Neoplasms",
            "mapping_confidence": 0.8,
            "source_text_fragment": "Conditions: Breast Neoplasms",
            "mapping_rationale": "Text explicitly states 'Breast Neoplasms' as a condition, commonly interpreted as malignant in oncology contexts with minor interpretation.",
            "id": "cb81c4f6-33f9-4f3c-85cf-82ad3f0911e8"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Sex",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "sex",
              "display": "Sex"
            },
            "value": "female",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Female patients, age 18~40",
            "mapping_rationale": "Explicit statement of patient sex.",
            "id": "61724742-6c56-4902-9785-4548e7a87e1a"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Age",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "age",
              "display": "Age"
            },
            "value": "18-40 years",
            "mapping_confidence": 1.0,
            "source_text_fragment": "age 18~40",
            "mapping_rationale": "Explicit age range provided.",
            "id": "95acf4c7-a16b-4620-b0bd-4336427fdf0a"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "adenocarcinoma of the breast",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Unilateral, operable, histologically confirmed adenocarcinoma of the breast",
            "mapping_rationale": "Direct diagnosis statement.",
            "id": "c5e87968-bd21-4f6f-84c2-dbcb88104664"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "I-III",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Stage I-III",
            "mapping_rationale": "Explicit cancer stage.",
            "id": "04f734e7-bc1b-497f-b753-15254fa7cd29"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Biomarker",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "biomarker",
              "display": "Biomarker"
            },
            "value": "positive",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer: the immunohistochemical cut-off for ER positive status was 1% or more staining in nuclei",
            "mapping_rationale": "Direct biomarker status.",
            "id": "836a3093-eb9d-468b-b2dd-9ecded267e81"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Biomarker",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "biomarker",
              "display": "Biomarker"
            },
            "value": "negative",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test by chemotherapy",
            "mapping_rationale": "Direct biomarker status.",
            "id": "a0c01c33-ecba-46b5-9a26-28367775e5b4"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "LymphNodeInvolvement",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "lymphnodeinvolvement",
              "display": "LymphNodeInvolvement"
            },
            "value": "positive",
            "mapping_confidence": 1.0,
            "source_text_fragment": "pathologically confirmed regional node-positive disease",
            "mapping_rationale": "Direct statement of lymph node status.",
            "id": "f2a25804-2143-4bb5-9fa2-d9f671d51246"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "surgery",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Primary surgery with clear margins plus axillary dissection",
            "mapping_rationale": "Explicit treatment description.",
            "id": "d6e7e474-856e-40ed-ab77-17dfc568ec94"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "PerformanceStatus",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "performancestatus",
              "display": "PerformanceStatus"
            },
            "value": "0-1",
            "mapping_confidence": 1.0,
            "source_text_fragment": "ECOG performance status 0-1",
            "mapping_rationale": "Direct performance status.",
            "id": "9504927e-f0b5-48f8-be68-3b41691badfa"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history.",
            "mapping_rationale": "Explicit mention of 'breast cancer' in the text.",
            "id": "9140a424-b056-4101-97cb-d24fe2446374"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Paclitaxel",
            "mapping_confidence": 1.0,
            "source_text_fragment": "The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients.",
            "mapping_rationale": "Explicit mention of 'paclitaxel' as part of treatment strategies.",
            "id": "d9a3d36a-2317-4e7c-b173-b9a3c1ef4c45"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Anthracycline-based regimens",
            "mapping_confidence": 1.0,
            "source_text_fragment": "The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients.",
            "mapping_rationale": "Explicit mention of 'anthracycline-based regimens' as part of treatment strategies.",
            "id": "2e76629a-7b26-409f-b12c-d847759b3e8a"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Age",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "age",
              "display": "Age"
            },
            "value": "Young",
            "mapping_confidence": 0.6,
            "source_text_fragment": "Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history.",
            "mapping_rationale": "Mention of 'young' describing the patient population, though not quantified, requiring moderate interpretation.",
            "id": "5210df53-56c3-4824-92f6-75e9ab4240b4"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Breast Cancer Patients",
            "mapping_rationale": "Explicitly stated in officialTitle",
            "id": "83b79dff-d31e-4a30-9bec-fa02e392980c"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Adjuvant Therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "as Adjuvant Therapy",
            "mapping_rationale": "Explicitly stated in titles",
            "id": "d45d59e0-4592-4962-aba4-26a61e6cae70"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "EC-wP",
            "mapping_confidence": 0.7,
            "source_text_fragment": "EC-wP",
            "mapping_rationale": "Abbreviation for treatment regimen, explicitly stated",
            "id": "a23458f8-0f6c-4096-8a3f-baa4ed7617e8"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "EP-wP",
            "mapping_confidence": 0.7,
            "source_text_fragment": "EP-wP",
            "mapping_rationale": "Abbreviation for treatment regimen, explicitly stated",
            "id": "545e7150-e5a0-44f9-8d40-19a9d4272850"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Age",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "age",
              "display": "Age"
            },
            "value": "less than 40 years old",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Less Than 40 Years Old",
            "mapping_rationale": "Explicitly stated demographic detail",
            "id": "b4baf83e-1e5d-4245-b6b0-9908420c6d3e"
          }
        ],
        "source_references": [],
        "validation": {
          "valid": true,
          "errors": [],
          "warnings": [],
          "compliance_score": 1.0
        },
        "metadata": {
          "pipeline_version": "Mcode_pipeline_v1",
          "engine_type": "LLM",
          "entities_count": 0,
          "mapped_count": 19,
          "compliance_score": 1.0,
          "token_usage": {
            "prompt_tokens": 829,
            "completion_tokens": 7562,
            "total_tokens": 8391
          },
          "aggregate_token_usage": {
            "prompt_tokens": 0,
            "completion_tokens": 0,
            "total_tokens": 0,
            "model_name": "",
            "provider_name": ""
          }
        },
        "error": null
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06650748",
          "orgStudyIdInfo": {
            "id": "OBU-BC-II-164"
          },
          "organization": {
            "fullName": "Peking University",
            "class": "OTHER"
          },
          "briefTitle": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer",
          "officialTitle": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: a Randomize-controlled Study"
        },
        "statusModule": {
          "statusVerifiedDate": "2024-10",
          "overallStatus": "NOT_YET_RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2024-11-15",
            "type": "ESTIMATED"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-10-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-04-01",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2024-10-18",
          "studyFirstSubmitQcDate": "2024-10-18",
          "studyFirstPostDateStruct": {
            "date": "2024-10-21",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2024-10-20",
          "lastUpdatePostDateStruct": {
            "date": "2024-10-26",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "Tao OUYANG",
            "investigatorTitle": "Professor",
            "investigatorAffiliation": "Peking University"
          },
          "leadSponsor": {
            "name": "Peking University",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": true,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "This is a prospective, single-center, randomize-controlled study. The purpose of this study is to evaluate the efficacy of neoadjuvant CDK4/6 inhibitors in patients with high-risk EPclin multigene risk analysis and non-response to Ki-67 2W, and to explore predictive biomarkers for sensitivity to CDK4/6 inhibitor therapy.",
          "detailedDescription": "China is a country with a high incidence of breast cancer. For operable hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer, traditional neoadjuvant chemotherapy often fails to achieve clinical complete response (CCR) and has poor tolerability. Endocrine therapy plays a significant role in the treatment of advanced and early-stage HR+/HER2- breast cancer, but its efficacy in neoadjuvant settings needs further exploration. Studies have shown that the CCR and breast conservation rate of neoadjuvant endocrine therapy for HR+/HER2- breast cancer are similar to those of neoadjuvant chemotherapy, with lower toxicity. Therefore, by precisely stratifying the recurrence risk of HR+/HER2- patients and treating them according to different risk levels, the response rate to neoadjuvant endocrine therapy can be further improved, which would be more beneficial for the patients. With the clinical application of CDK4/6 inhibitors, the effectiveness of neoadjuvant endocrine therapy is expected to be enhanced.\n\nIn PALLET study, the combination of palbociclib and letrozole significantly inhibited Ki-67 expression, leading to a higher number of patients achieving a state of cell cycle arrest (CCCA) (defined as Ki-67\u22642.7%). NeoMONARCH study suggests that a regimen containing abemaciclib is significantly superior to anastrozole monotherapy, with statistical significance (P \\< 0.001). The NeoPAL and CORALLEEN studies indicate that neoadjuvant endocrine therapy with palbociclib or ribociclib is comparable in efficacy to neoadjuvant chemotherapy, yet has fewer side effects.\n\nEndoPredict (12-gene assay, EPclin) is a second-generation multigene testing scoring tool that combines the molecular biological status of the tumor with clinical factors (tumor size and lymph node status). For early-stage HR+/HER2- breast cancer patients, the EPclin test result helps to distinguish between low and high recurrence risk populations, allowing for a more precise assessment of patient prognosis. In the validation study for premenopausal patients, a total of 385 patients with stage \u2264pT3 and pN0\\~1, who received only endocrine therapy for ER+/HER2- early invasive breast cancer, were enrolled. The results showed that the 10-year distant recurrence-free survival (DRFS) rate for patients in the EPclin low-risk group reached 97%, while the 10-year DRFS rate for the EPclin high-risk group was 76% (P=0.004). For postmenopausal patients, the prognostic value of EPclin was independently validated through the ABCSG6\\&8 study. The study included 1,702 patients with ER+/HER2- early invasive breast cancer who underwent surgery and received only five years of endocrine therapy. The results showed that the 10-year distant recurrence rate for patients in the EPclin low-risk group was 4%, while the 10-year distant recurrence rates for patients in the EPclin high-risk group were 28% and 22% (P\\<0.001). A retrospective analysis of ABCSG-34 demonstrated that for patients undergoing neoadjuvant endocrine therapy, the application of EPclin for prognostic assessment revealed a negative correlation between risk levels and residual cancer burden (RCB). That is, among patients receiving neoadjuvant endocrine therapy (NET), a higher proportion of low-risk patients compared to high-risk patients ultimately had an RCB of 0-I.\n\nThis study focuses on early-stage HR+/HER2- breast cancer, conducting recurrence risk analysis through EPclin multigene testing, and integrating the dynamic changes of Ki67 after two weeks of neoadjuvant endocrine therapy. Patients are risk-stratified and treated with or without CDK4/6 inhibitors. The study explores the improvement in PEPI scores after surgery and analyzes the effectiveness of multigene testing combined with Ki67 dynamic changes as a predictor for the efficacy of CDK4/6 inhibitor treatment in HR+/HER2- breast cancer with high recurrence risk and insensitivity to endocrine therapy. The study also seeks to explore methods for predicting sensitivity to CDK4/6 inhibitor treatment."
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer",
            "Early-stage Breast Cancer"
          ],
          "keywords": [
            "Early-stage Breast Cancer",
            "neoadjuvant endocrine therapy",
            "CDK4/6",
            "HR+/HER2-"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "PARALLEL",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Arm 1",
              "type": "EXPERIMENTAL",
              "description": "gene high-risk according to Epclin who are insensitive to single-agent AI treatment for two weeks",
              "interventionNames": [
                "Drug: Dalpiciclib",
                "Drug: Letrozole"
              ]
            },
            {
              "label": "Arm 2",
              "type": "EXPERIMENTAL",
              "description": "gene high-risk according to Epclin who are sensitive to single-agent AI treatment for two weeks and gene low-risk according to Epclin who are insensitive to single-agent AI treatment for two weeks, randomly assigned to letrozole treatment arm",
              "interventionNames": [
                "Drug: Letrozole"
              ]
            },
            {
              "label": "Arm 3",
              "type": "EXPERIMENTAL",
              "description": "gene high-risk according to Epclin who are sensitive to single-agent AI treatment for two weeks and gene low-risk according to Epclin who are insensitive to single-agent AI treatment for two weeks, randomly assigned to Dalpiciclib and letrozole treatment arm",
              "interventionNames": [
                "Drug: Dalpiciclib",
                "Drug: Letrozole"
              ]
            },
            {
              "label": "Arm 4",
              "type": "EXPERIMENTAL",
              "description": "gene low-risk according to Epclin who are sensitive to single-agent AI treatment for two weeks",
              "interventionNames": [
                "Drug: Letrozole"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Dalpiciclib",
              "description": "Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.",
              "armGroupLabels": [
                "Arm 1",
                "Arm 3"
              ]
            },
            {
              "type": "DRUG",
              "name": "Letrozole",
              "description": "2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage",
              "armGroupLabels": [
                "Arm 1",
                "Arm 2",
                "Arm 3",
                "Arm 4"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "1. The proportion of (PEPI score 0 + pCR) in patients with discordant EPclin scores and Ki67 assessments who were randomly assigned to the \"+CDK4/6i\" group",
              "description": "proportion of subjects who were PEPI score 0 or pCR after neoadjuvant endocrine therapy in patients with discordant EPclin scores and Ki67 assessments who were randomly assigned to the \"+CDK4/6i\" group",
              "timeFrame": "Start of treatment until 6-month follow-up"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "The change in Ki-67 compared to the baseline after two weeks of treatment",
              "timeFrame": "Start of treatment until 2-week follow-up"
            },
            {
              "measure": "The change in Ki-67 after surgery compared to two weeks post-treatment",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "Rate of patients with pCR (pathological complete response) after surgery",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "ORR",
              "description": "Objective response rate: proportion of subjects who achieved complete remission (CR) or partial remission (PR) by primary tumor imaging evaluation",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "CCCA rate",
              "description": "Cell cycle arrest: defined as Ki-67\u22642.7%",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "Breast conservation rate",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "The proportion of PEPI 0-1 in patients with gene-high risk who are sensitive to single-agent AI treatment for two weeks and treated with AI in combination with Dalpiciclib",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "The proportion of PEPI 0-1 in patients with gene-low risk who are insensitive to single-agent AI treatment for two weeks and treated with AI in combination with Dalpiciclib",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "The proportion of patients at high risk according to Epclin who are downgraded to low risk after neoadjuvant treatment",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "EFS",
              "description": "Event free survival: time from the start of treatment to the first occurrence of any of the following events: disease progression, local or distant recurrence, or death due to any cause",
              "timeFrame": "Start of treatment until 24-month follow-up"
            },
            {
              "measure": "Incidence of adverse events (AE)",
              "timeFrame": "Start of treatment until 6-month follow-up"
            },
            {
              "measure": "Incidence of serious adverse events (SAE)",
              "timeFrame": "Start of treatment until 6-month follow-up"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n1. Females aged 18 to 70 years;\n2. Patients with histologically confirmed HR+/HER2- invasive breast cancer that is sensitive to endocrine therapy. Tumor diameter \\>2 cm, clinically positive axillary lymph nodes not more than 2 (T2N1M0), Ki67\u2265+20%. Endocrine therapy sensitivity is defined as ER expression \\>50% by immunohistochemistry. HER-2 negativity is defined as HER-2 results of 0 or 1+ by immunohistochemistry, or negative by FISH;\n3. Within 28 days before the first dose of study medication, patients must have at least one measurable lesion according to RECIST 1.1 standards, as assessed by ultrasound or MRI;\n4. Laboratory test values: a. Absolute neutrophil count (ANC) \u2265 1,500/mm3 (1.5 \u00d7 10\\^9/L); b. Platelet count (PLT) \u2265 100,000/mm3 (100 \u00d7 10\\^9/L); c. Hemoglobin (Hb) \u2265 9 g/dL (90 g/L); d. Serum creatinine \u2264 1.5 times the upper limit of normal (ULN) or creatinine clearance \u2265 30 ml/min (based on the Cockroft-Gault formula); e. Total bilirubin (BIL) \u2264 1.5 times the upper limit of normal (ULN), Gilbert's syndrome; f. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels \u2264 2.5 times the upper limit of normal (ULN); g. INR or PT \u22641.5 ULN, APTT \u22641.5 ULN.\n5. Subject agrees to collect tumor biopsy specimen during the screening period;\n6. Subject signed the informed consent form, expressing willingness and ability to comply with the planned visits, study treatments, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n1. Coexisted with other malignant tumors within 5 years prior to first medication, except for cured squamous cell carcinoma of the skin, basal cell carcinoma, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix/breast, etc;\n2. Had a serious infection within 1 month before screening or required systemic treatment for any active infection within 2 weeks before first medication;\n3. History or current presence of autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener's syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis), autoimmune hepatitis, systemic sclerosis (scleroderma, etc.), Hashimoto's thyroiditis (exceptions are noted below), autoimmune vasculitis, autoimmune neuropathy (Guillain-Barre syndrome), etc. The following exceptions apply: Type I diabetes, thyroid dysfunction requiring only hormone replacement therapy (including thyroid dysfunction caused by autoimmune thyroid disease), psoriasis or vitiligo not requiring systemic treatment;\n4. History of organ transplantation or allogeneic hematopoietic stem cell transplantation;\n5. Patients who received systemic anti-cancer treatment within 2 weeks before the first dose, including chemotherapy, immunotherapy, hormone therapy, biological therapy (cytokines or growth factors that control the progression of cancer);\n6. Metastatic breast cancer;\n7. Positive for human immunodeficiency virus antibodies (HIV-Ab) or syphilis antibodies (Anti-TP); positive for hepatitis C virus antibodies (HCV-Ab), with hepatitis C virus RNA quantification \\> the upper limit of the normal value of the detection unit; positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (HBcAb), with HBV DNA quantification \\> the lower limit of detection of the detection unit;\n8. History of alcohol abuse or drug abuse.",
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "genderBased": true,
          "minimumAge": "18 Years",
          "maximumAge": "70 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "centralContacts": [
            {
              "name": "Zhaoqing Fan, PhD",
              "role": "CONTACT",
              "phone": "13601052226",
              "email": "zhqfan@bjmu.edu.cn"
            }
          ],
          "overallOfficials": [
            {
              "name": "Zhaoqing Fan",
              "affiliation": "Peking University Cancer Hospital & Institute",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Beijing Cancer Hospital",
              "city": "Beijing",
              "country": "China",
              "contacts": [
                {
                  "name": "Zhaoqing Fan",
                  "role": "CONTACT"
                }
              ],
              "geoPoint": {
                "lat": 39.9075,
                "lon": 116.39723
              }
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO"
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2025-09-08"
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D001943",
              "term": "Breast Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D009369",
              "term": "Neoplasms"
            },
            {
              "id": "D001941",
              "term": "Breast Diseases"
            },
            {
              "id": "D012871",
              "term": "Skin Diseases"
            },
            {
              "id": "D017437",
              "term": "Skin and Connective Tissue Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "C000720752",
              "term": "dalpiciclib"
            },
            {
              "id": "D000077289",
              "term": "Letrozole"
            }
          ],
          "ancestors": [
            {
              "id": "D009570",
              "term": "Nitriles"
            },
            {
              "id": "D009930",
              "term": "Organic Chemicals"
            },
            {
              "id": "D014230",
              "term": "Triazoles"
            },
            {
              "id": "D001393",
              "term": "Azoles"
            },
            {
              "id": "D006573",
              "term": "Heterocyclic Compounds, 1-Ring"
            },
            {
              "id": "D006571",
              "term": "Heterocyclic Compounds"
            }
          ]
        }
      },
      "hasResults": false,
      "McodeResults": {
        "extracted_entities": [],
        "mcode_mappings": [
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Breast Cancer",
            "mapping_rationale": "Explicitly stated diagnosis of breast cancer in the conditions list",
            "id": "f0652c64-f2a0-4852-b150-a855785a62c2"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "early-stage",
            "mapping_confidence": 0.9,
            "source_text_fragment": "Early-stage Breast Cancer",
            "mapping_rationale": "Explicitly stated early-stage breast cancer, implying early stage but not formal TNM staging",
            "id": "85fd94dd-4c10-43eb-a17c-e7a9774cabe6"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "HR+/HER2- invasive breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Patients with histologically confirmed HR+/HER2- invasive breast cancer that is sensitive to endocrine therapy.",
            "mapping_rationale": "Direct statement of cancer diagnosis with biomarker status.",
            "id": "2ac3c45e-e832-4ec8-a3e6-53460e515749"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "T2N1M0",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Tumor diameter >2 cm, clinically positive axillary lymph nodes not more than 2 (T2N1M0)",
            "mapping_rationale": "Explicit TNM staging provided.",
            "id": "dfa603f9-210c-4084-a5de-c690c05f7055"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TumorMarkerTest",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tumormarkertest",
              "display": "TumorMarkerTest"
            },
            "value": "\u226520%",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Ki67\u2265+20%",
            "mapping_rationale": "Direct statement of Ki-67 value.",
            "id": "b5355538-7bd1-4fd0-9736-9ffed720c53b"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TumorMarkerTest",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tumormarkertest",
              "display": "TumorMarkerTest"
            },
            "value": ">50%",
            "mapping_confidence": 1.0,
            "source_text_fragment": "ER expression >50% by immunohistochemistry",
            "mapping_rationale": "Direct statement of ER status.",
            "id": "a974e63b-bd79-4213-853d-2317e717112f"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TumorMarkerTest",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tumormarkertest",
              "display": "TumorMarkerTest"
            },
            "value": "negative",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER-2 negativity is defined as HER-2 results of 0 or 1+ by immunohistochemistry, or negative by FISH",
            "mapping_rationale": "Explicit definition of HER2 negativity.",
            "id": "2cac4223-0d08-48b7-b554-ca8943594fea"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Sex",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "sex",
              "display": "Sex"
            },
            "value": "female",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Females aged 18 to 70 years",
            "mapping_rationale": "Direct statement of patient sex.",
            "id": "0fc1f421-0e34-434f-aa0b-dd5b2070c377"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Age",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "age",
              "display": "Age"
            },
            "value": "18-70 years",
            "mapping_confidence": 1.0,
            "source_text_fragment": "minimumAge: 18 Years maximumAge: 70 Years",
            "mapping_rationale": "Explicit statement of age range.",
            "id": "00812de7-d38e-4cbb-8254-5828b8f44d62"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "HR+/HER2- breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer",
            "mapping_rationale": "Explicitly stated cancer type in the text",
            "id": "3a5fbe1a-1a5b-48e5-8b3f-6f8edc13fb3a"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerStageGroup",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancerstagegroup",
              "display": "CancerStageGroup"
            },
            "value": "early-stage",
            "mapping_confidence": 0.8,
            "source_text_fragment": "early-stage HR+/HER2- breast cancer",
            "mapping_rationale": "Stated as early-stage for the study population, though not specific TNM",
            "id": "f4c9df7d-02ee-491c-b5eb-9925e554ed6e"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "CDK4/6 inhibitors",
            "mapping_confidence": 1.0,
            "source_text_fragment": "evaluate the efficacy of neoadjuvant CDK4/6 inhibitors",
            "mapping_rationale": "Directly stated treatment intervention in the study",
            "id": "888987f7-4215-44fd-bd80-0e7d21a956c3"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "endocrine therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "neoadjuvant endocrine therapy for HR+/HER2- breast cancer",
            "mapping_rationale": "Explicitly mentioned as part of the treatment approach",
            "id": "a2c97fe1-7ea2-4384-be9f-3ca060f3aaed"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TumorMarkerTest",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tumormarkertest",
              "display": "TumorMarkerTest"
            },
            "value": "non-response after 2 weeks",
            "mapping_confidence": 1.0,
            "source_text_fragment": "non-response to Ki-67 2W",
            "mapping_rationale": "Directly stated marker and response criteria in the study",
            "id": "f4920560-a71c-44a0-ae95-a34b9253630c"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "RiskAssessment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "riskassessment",
              "display": "RiskAssessment"
            },
            "value": "high-risk",
            "mapping_confidence": 1.0,
            "source_text_fragment": "high-risk EPclin multigene risk analysis",
            "mapping_rationale": "Explicitly stated risk assessment result for inclusion",
            "id": "75e72a08-3fe5-4042-acea-5890283c4e0c"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "PrognosticScore",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "prognosticscore",
              "display": "PrognosticScore"
            },
            "value": "PEPI score",
            "mapping_confidence": 1.0,
            "source_text_fragment": "the study explores the improvement in PEPI scores after surgery",
            "mapping_rationale": "Directly mentioned as an outcome measure in the study",
            "id": "ce1e76f1-45cc-49a7-9e86-c83318e84f3f"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "HR+/HER2- Breast Cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer",
            "mapping_rationale": "Explicitly states the cancer diagnosis in the brief title.",
            "id": "0451bad3-bffe-4bb3-85b6-e87bc065a326"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Endocrine Therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer",
            "mapping_rationale": "Explicitly mentions endocrine therapy as part of treatment in the brief title.",
            "id": "da4056d7-9363-41a5-9071-cac29e11b6fc"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "CDK4/6 Inhibitors",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer",
            "mapping_rationale": "Explicitly mentions CDK4/6 inhibitors as part of treatment options in the brief title.",
            "id": "0f03fbfc-d2c3-402a-9907-a11977c73318"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TumorMarkerTest",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tumormarkertest",
              "display": "TumorMarkerTest"
            },
            "value": "Ki-67 Dynamic Assessment",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer",
            "mapping_rationale": "Explicitly mentions Ki-67 assessment in the brief title.",
            "id": "cf8b05f6-c084-4e41-aabe-d3be1de427b5"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "GeneticVariant",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "geneticvariant",
              "display": "GeneticVariant"
            },
            "value": "Multigene Risk Score",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer",
            "mapping_rationale": "Explicitly mentions multigene risk score in the brief title.",
            "id": "dc763e64-3920-49a6-beb0-32217c6968cb"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "ResearchStudy",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "researchstudy",
              "display": "ResearchStudy"
            },
            "value": "Randomize-controlled",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: a Randomize-controlled Study",
            "mapping_rationale": "Explicitly states the study design in the official title.",
            "id": "ef97524e-6fcf-449b-863a-86514003d517"
          }
        ],
        "source_references": [],
        "validation": {
          "valid": true,
          "errors": [],
          "warnings": [],
          "compliance_score": 1.0
        },
        "metadata": {
          "pipeline_version": "Mcode_pipeline_v1",
          "engine_type": "LLM",
          "entities_count": 0,
          "mapped_count": 22,
          "compliance_score": 1.0,
          "token_usage": {
            "prompt_tokens": 867,
            "completion_tokens": 10582,
            "total_tokens": 11449
          },
          "aggregate_token_usage": {
            "prompt_tokens": 0,
            "completion_tokens": 0,
            "total_tokens": 0,
            "model_name": "",
            "provider_name": ""
          }
        },
        "error": null
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00109785",
          "orgStudyIdInfo": {
            "id": "MSKCC-97046"
          },
          "secondaryIdInfos": [
            {
              "id": "CDR0000065706",
              "type": "REGISTRY",
              "domain": "PDQ (Physician Data Query)"
            },
            {
              "id": "NCI-G97-1308"
            }
          ],
          "organization": {
            "fullName": "Memorial Sloan Kettering Cancer Center",
            "class": "OTHER"
          },
          "briefTitle": "PET Scans in Patients With Locally Advanced Breast Cancer",
          "officialTitle": "Positron Emitter I-124-Iododeoxyuridine to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis"
        },
        "statusModule": {
          "statusVerifiedDate": "2015-12",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "1997-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2008-12",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2005-05-03",
          "studyFirstSubmitQcDate": "2005-05-03",
          "studyFirstPostDateStruct": {
            "date": "2005-05-04",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2015-12-23",
          "lastUpdatePostDateStruct": {
            "date": "2015-12-24",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Memorial Sloan Kettering Cancer Center",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "National Cancer Institute (NCI)",
              "class": "NIH"
            }
          ]
        },
        "descriptionModule": {
          "briefSummary": "RATIONALE: Imaging procedures such as PET scans may improve the ability to monitor the effectiveness of chemotherapy for locally advanced breast cancer.\n\nPURPOSE: This clinical trial is studying how well PET scans work in patients with locally advanced breast cancer who will undergo chemotherapy.",
          "detailedDescription": "OBJECTIVES:\n\n* Determine whether the biologic activity of locally advanced breast cancer as measured by retention of iodine I 124 iododeoxyuridine (IUdR) on positron emission tomography (PET) scans pre- and postchemotherapy is different between patients whose tumor shrinks after treatment in comparison to patients whose tumor is stable or continues to grow.\n* Demonstrate that incorporation of IUdR into tumor is in the tumor DNA at 24-36 hours post injection, as documented by tissue analysis and immunohistochemistry and that this correlates with the subsequent change in tumor dimension and proliferative activity of the tumor.\n* Compare the pre and post treatment results of fludeoxyglucose (FDG) PET scanning and IUdR PET scanning in the same breast lesions as a basis for assessment of the relative metabolic change during chemotherapy.\n* Further assess the biologic activity of metastatic tumor sites and their changes in size following chemotherapy to standard parameters that are used to evaluate change in tumor size, obtained under clinical standard of care for breast cancer, which will include CT scans as well as bone scans.\n* Assess the accuracy of noninvasive measurement of PET measurement of the left ventricular cardiac chamber clearance of radioactivity as a substitute for arterial plasma sampling for determining metabolic rates of FDG and IUdR uptake into tumors.\n* Evaluate metabolic changes in tumors as they are affected by specific chemotherapy in comparison to changes in tumor dimensions.\n\nOUTLINE: For this study, the chemotherapy administered for an individual patient is at the discretion of the patient's primary attending physician. After chemotherapy, the patient is evaluated for surgical resection of the tumor. If the tumor is unresectable, the patient may be offered radiation therapy.\n\nThe first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy.\n\nThe PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.\n\nPROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study."
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ],
          "keywords": [
            "stage IIIA breast cancer",
            "stage IIIB breast cancer",
            "stage IIIC breast cancer",
            "male breast cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "DIAGNOSTIC",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "PET Scans",
              "type": "EXPERIMENTAL",
              "description": "The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.",
              "interventionNames": [
                "Procedure: positron emission tomography",
                "Radiation: fludeoxyglucose F 18",
                "Radiation: iodine I 124 iododeoxyuridine"
              ]
            }
          ],
          "interventions": [
            {
              "type": "PROCEDURE",
              "name": "positron emission tomography",
              "armGroupLabels": [
                "PET Scans"
              ]
            },
            {
              "type": "RADIATION",
              "name": "fludeoxyglucose F 18",
              "armGroupLabels": [
                "PET Scans"
              ]
            },
            {
              "type": "RADIATION",
              "name": "iodine I 124 iododeoxyuridine",
              "armGroupLabels": [
                "PET Scans"
              ]
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed locally advanced breast carcinoma\n\n  * Stage T3 T4, N2 or N3 disease\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Male or female\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* Karnofsky 80-100%\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* Not specified\n\nRenal:\n\n* Not specified\n\nOther:\n\n* No history of psychiatric illness that would preclude giving informed consent\n* Not pregnant\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Teresa Ann Gilewski, MD",
              "affiliation": "Memorial Sloan Kettering Cancer Center",
              "role": "STUDY_CHAIR"
            }
          ],
          "locations": [
            {
              "facility": "Memorial Sloan-Kettering Cancer Center",
              "city": "New York",
              "state": "New York",
              "zip": "10065",
              "country": "United States",
              "geoPoint": {
                "lat": 40.71427,
                "lon": -74.00597
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2025-09-08"
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D001943",
              "term": "Breast Neoplasms"
            },
            {
              "id": "D018567",
              "term": "Breast Neoplasms, Male"
            }
          ],
          "ancestors": [
            {
              "id": "D009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D009369",
              "term": "Neoplasms"
            },
            {
              "id": "D001941",
              "term": "Breast Diseases"
            },
            {
              "id": "D012871",
              "term": "Skin Diseases"
            },
            {
              "id": "D017437",
              "term": "Skin and Connective Tissue Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D009682",
              "term": "Magnetic Resonance Spectroscopy"
            },
            {
              "id": "D019788",
              "term": "Fluorodeoxyglucose F18"
            }
          ],
          "ancestors": [
            {
              "id": "D013057",
              "term": "Spectrum Analysis"
            },
            {
              "id": "D002623",
              "term": "Chemistry Techniques, Analytical"
            },
            {
              "id": "D008919",
              "term": "Investigative Techniques"
            },
            {
              "id": "D003847",
              "term": "Deoxyglucose"
            },
            {
              "id": "D003837",
              "term": "Deoxy Sugars"
            },
            {
              "id": "D002241",
              "term": "Carbohydrates"
            }
          ]
        }
      },
      "hasResults": false,
      "McodeResults": {
        "extracted_entities": [],
        "mcode_mappings": [
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Conditions: Breast Cancer",
            "mapping_rationale": "Directly stated cancer condition in the text.",
            "id": "dcad327e-e45a-4b56-8f3a-f99d03f36ec4"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Locally advanced breast carcinoma",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Histologically confirmed locally advanced breast carcinoma",
            "mapping_rationale": "Explicitly stated diagnosis",
            "id": "1fb11e61-eaeb-4a7f-9919-eceb81c4fb95"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "T3 or T4",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Stage T3 T4, N2 or N3 disease",
            "mapping_rationale": "Explicit T stage range stated",
            "id": "5d9c1762-d3ca-45b3-91fe-18eabdd99ff0"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "N2 or N3",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Stage T3 T4, N2 or N3 disease",
            "mapping_rationale": "Explicit N stage range stated",
            "id": "2c0bb9c7-8d59-4a5a-b6aa-d07c2bed9368"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "PerformanceStatus",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "performancestatus",
              "display": "PerformanceStatus"
            },
            "value": "80-100%",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Karnofsky 80-100%",
            "mapping_rationale": "Explicit performance status stated",
            "id": "c8947d39-9ebb-45cb-bec8-25a955076c6e"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Age",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "age",
              "display": "Age"
            },
            "value": "18 to 120 years",
            "mapping_confidence": 1.0,
            "source_text_fragment": "minimumAge: 18 Years maximumAge: 120 Years",
            "mapping_rationale": "Explicit age range stated",
            "id": "e7444bb2-87a6-419b-af6b-47bf1713285b"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Sex",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "sex",
              "display": "Sex"
            },
            "value": "Male or female",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Sex: * Male or female",
            "mapping_rationale": "Explicit sex criteria stated",
            "id": "2a329335-689a-49bc-9dca-fb720b41a13d"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "locally advanced breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "patients with locally advanced breast cancer who will undergo chemotherapy",
            "mapping_rationale": "Explicit mention of cancer diagnosis",
            "id": "c03285e2-94e5-4bf8-a8c2-a7f63697635a"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "chemotherapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "chemotherapy administered for an individual patient is at the discretion of the patient's primary attending physician",
            "mapping_rationale": "Explicit mention of chemotherapy treatment",
            "id": "1c213b57-083e-4c7b-9b4b-87aeb9331439"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "surgical resection of the tumor",
            "mapping_confidence": 1.0,
            "source_text_fragment": "After chemotherapy, the patient is evaluated for surgical resection of the tumor",
            "mapping_rationale": "Explicit mention of surgical treatment",
            "id": "2ac1d69b-a821-45d3-9fe5-f903feafe874"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "radiation therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "If the tumor is unresectable, the patient may be offered radiation therapy",
            "mapping_rationale": "Explicit mention of radiation therapy treatment",
            "id": "b67e1e32-d385-4f08-bc40-e2db0741933a"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Locally advanced breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "PET Scans in Patients With Locally Advanced Breast Cancer",
            "mapping_rationale": "The brief title explicitly states the cancer condition with staging descriptor.",
            "id": "71d56750-37d6-469f-9265-c2035daf6113"
          }
        ],
        "source_references": [],
        "validation": {
          "valid": true,
          "errors": [],
          "warnings": [],
          "compliance_score": 1.0
        },
        "metadata": {
          "pipeline_version": "Mcode_pipeline_v1",
          "engine_type": "LLM",
          "entities_count": 0,
          "mapped_count": 12,
          "compliance_score": 1.0,
          "token_usage": {
            "prompt_tokens": 848,
            "completion_tokens": 8138,
            "total_tokens": 8986
          },
          "aggregate_token_usage": {
            "prompt_tokens": 0,
            "completion_tokens": 0,
            "total_tokens": 0,
            "model_name": "",
            "provider_name": ""
          }
        },
        "error": null
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00616135",
          "orgStudyIdInfo": {
            "id": "RESTORE-2"
          },
          "organization": {
            "fullName": "Cytori Therapeutics",
            "class": "INDUSTRY"
          },
          "briefTitle": "Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy",
          "officialTitle": "A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study.",
          "acronym": "RESTORE-2"
        },
        "statusModule": {
          "statusVerifiedDate": "2011-05",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2008-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2010-11",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2008-02-05",
          "studyFirstSubmitQcDate": "2008-02-05",
          "studyFirstPostDateStruct": {
            "date": "2008-02-15",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2011-05-13",
          "lastUpdatePostDateStruct": {
            "date": "2011-05-17",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "oldNameTitle": "Sean Gemmill, MS, RAC; Clinical Research Manager",
            "oldOrganization": "Cytori Therapeutics"
          },
          "leadSponsor": {
            "name": "Cytori Therapeutics",
            "class": "INDUSTRY"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "A post-marketing study evaluating the transplantation of autologous fat augmented with Adipose Derived Regenerative Cells (ADRCs), in patients with functional and cosmetic breast deformities post segmental mastectomy or quadrantectomy (lumpectomy)."
        },
        "conditionsModule": {
          "conditions": [
            "Breast Neoplasms",
            "Carcinoma, Ductal, Breast",
            "Mammaplasty",
            "Mastectomy, Segmental, Lumpectomy, Breast Reconstruction,"
          ],
          "keywords": [
            "Breast",
            "Stem Cell",
            "Adipose Derived Stem Cells",
            "Adipose Derived Regenerative Cells",
            "ADRC",
            "Reconstructive Breast Surgery",
            "Breast Reconstruction",
            "Cancer",
            "Carcinoma",
            "Autologous fat transplantation",
            "Autologous fat",
            "Cosmetic breast deformities",
            "Functional breast deformity",
            "Lumpectomy",
            "Segmental mastectomy",
            "Quadrantectomy",
            "breast conservation therapy"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE4"
          ],
          "designInfo": {
            "allocation": "NON_RANDOMIZED",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 71,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "type": "PROCEDURE",
              "name": "ADRC-Enhanced Autologous Fat Transplant",
              "description": "Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy."
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Patient and physician satisfaction with functional and cosmetic results. Improvement in overall breast deformity measured at 12 months compared to baseline.",
              "timeFrame": "12 months"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Change in breast volume and shape at 6 and 12 Months compared to baseline. Improvement in skin pigmentation abnormalities at 6 and 12 months compared to Baseline. Improvement in overall breast deformity at 6 Months compared to Baseline.",
              "timeFrame": "6 months and 12 months"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Females with a history of T2N0M0 breast carcinoma (tumor \u22643 cm in largest dimension)\n* Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)\n* Clean surgical margins\n* No prosthesis in breast(s) to undergo treatment\n* Ability to undergo lipoaspiration\n* Last treatment for breast cancer \u2265 12 months prior to enrollment with absence of recurrence (patients on anti-estrogen adjuvant therapy are NOT excluded)\n* No evidence of recurrence of cancer based on mammogram or breast exam prior to enrollment\n* Objective signs of mild breast damage post Breast Conservation Therapy\n* Type I Cosmetic Sequelae Classification\n* A minimum of 1 cm of soft tissue (e.g. breast or fat) is available between the skin and chest wall at the recipient site\n* A minimum of two-thirds of the breast is remaining post Breast Conservation Therapy\n* No continuous adhesion of skin to bone \\>3 cm in diameter\n* The volume and shape of the defect(s) must be conducive to correction during a single treatment session (maximum defect volume \u2264150 mL in breast(s) to undergo treatment)\n\nExclusion Criteria:\n\n* History of autoimmune disorder (e.g., Systemic Lupus Erythematosus \\[SLE\\])\n* History of connective, metabolic or atrophic skin disease\n* History of keloid scarring\n* Chronic use (\\>7 consecutive days) of anticoagulants (such as aspirin) or NSAIDs within 15 days prior to enrollment\n* Life expectancy \u2264 2 years\n* Recurrence or active malignancy requiring radiation or surgical treatment \u226412 months prior to enrollment\n* Presence of any other known malignancy\n* Body Mass Index (BMI) \\>30\n* Plan to undergo weight reduction surgery or foresee any significant weight changes during the study (defined as changes in BMI \\>5 compared to baseline\n* Presence of contraindications to MRI",
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "locations": [
            {
              "facility": "Jules Bordet Institute of Cancer",
              "city": "Brussels",
              "country": "Belgium",
              "geoPoint": {
                "lat": 50.85045,
                "lon": 4.34878
              }
            },
            {
              "facility": "Universit\u00e0 degli Studi di Firenze",
              "city": "Florence",
              "zip": "50134",
              "country": "Italy",
              "geoPoint": {
                "lat": 43.77925,
                "lon": 11.24626
              }
            },
            {
              "facility": "Hospital General Universitario Gregorio Mara\u00f1on",
              "city": "Madrid",
              "zip": "28007",
              "country": "Spain",
              "geoPoint": {
                "lat": 40.4165,
                "lon": -3.70256
              }
            },
            {
              "facility": "Instituto Valenciano Oncologia",
              "city": "Valencia",
              "zip": "46009",
              "country": "Spain",
              "geoPoint": {
                "lat": 39.47391,
                "lon": -0.37966
              }
            },
            {
              "facility": "Glasgow Royal Infirmary",
              "city": "Glasgow",
              "state": "Scotland",
              "zip": "G4 0SF",
              "country": "United Kingdom",
              "geoPoint": {
                "lat": 55.86515,
                "lon": -4.25763
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2025-09-08",
          "removedCountries": [
            "France"
          ]
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D001943",
              "term": "Breast Neoplasms"
            },
            {
              "id": "D018270",
              "term": "Carcinoma, Ductal, Breast"
            },
            {
              "id": "D009369",
              "term": "Neoplasms"
            },
            {
              "id": "D002277",
              "term": "Carcinoma"
            }
          ],
          "ancestors": [
            {
              "id": "D009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D001941",
              "term": "Breast Diseases"
            },
            {
              "id": "D012871",
              "term": "Skin Diseases"
            },
            {
              "id": "D017437",
              "term": "Skin and Connective Tissue Diseases"
            },
            {
              "id": "D044584",
              "term": "Carcinoma, Ductal"
            },
            {
              "id": "D000230",
              "term": "Adenocarcinoma"
            },
            {
              "id": "D009375",
              "term": "Neoplasms, Glandular and Epithelial"
            },
            {
              "id": "D009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D018299",
              "term": "Neoplasms, Ductal, Lobular, and Medullary"
            }
          ]
        }
      },
      "hasResults": false,
      "McodeResults": {
        "extracted_entities": [],
        "mcode_mappings": [
          {
            "resourceType": "Observation",
            "mcode_element": "allocation",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "allocation",
              "display": "allocation"
            },
            "value": "NON_RANDOMIZED",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"allocation\": \"NON_RANDOMIZED\"",
            "mapping_rationale": "Direct statement of study allocation from design",
            "id": "8c2008fb-bb7d-46a4-bdfd-6edd6f91fff6"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "interventionModel",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "interventionmodel",
              "display": "interventionModel"
            },
            "value": "SINGLE_GROUP",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"interventionModel\": \"SINGLE_GROUP\"",
            "mapping_rationale": "Explicit statement of intervention model",
            "id": "de6aeef3-a46f-4929-8182-ac9a70000ea6"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "primaryPurpose",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "primarypurpose",
              "display": "primaryPurpose"
            },
            "value": "TREATMENT",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"primaryPurpose\": \"TREATMENT\"",
            "mapping_rationale": "Direct statement of primary purpose",
            "id": "91ded923-493c-4c89-9976-466800b51ef2"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "masking",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "masking",
              "display": "masking"
            },
            "value": "NONE",
            "mapping_confidence": 1.0,
            "source_text_fragment": "\"masking\": \"NONE\"",
            "mapping_rationale": "Explicit statement of masking information",
            "id": "f2f15ad6-be4a-45ac-8cea-b9fab31fdf45"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Neoplasms",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Breast Neoplasms",
            "mapping_rationale": "Explicitly stated cancer condition",
            "id": "8e57c513-d0c9-4283-8e27-d714319df882"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Carcinoma, Ductal, Breast",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Carcinoma, Ductal, Breast",
            "mapping_rationale": "Explicitly stated specific cancer type",
            "id": "8a11cecb-4743-41d3-8658-fa1f7462c49e"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Mastectomy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Mastectomy",
            "mapping_rationale": "Explicitly stated surgical treatment for cancer",
            "id": "70f3cbee-7802-4e68-8e7b-d795042ba098"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Lumpectomy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Lumpectomy",
            "mapping_rationale": "Explicitly stated surgical treatment for cancer",
            "id": "97b69ea3-4da1-484e-a1f3-58a2262357bd"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast carcinoma",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Females with a history of T2N0M0 breast carcinoma (tumor \u22643 cm in largest dimension)",
            "mapping_rationale": "Explicit statement of cancer diagnosis",
            "id": "a23c7d24-ea48-4d5e-b06b-c61f3d9828dc"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "T2N0M0",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Females with a history of T2N0M0 breast carcinoma (tumor \u22643 cm in largest dimension)",
            "mapping_rationale": "Explicit TNM staging information",
            "id": "6d05e9eb-05e1-4794-bf94-c13d5dc8a8ad"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Segmental mastectomy or quadrantectomy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)",
            "mapping_rationale": "Explicit description of surgical treatment",
            "id": "bf27301d-180a-44d0-8c33-edbfe63ecf15"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Sex",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "sex",
              "display": "Sex"
            },
            "value": "Female",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Females with a history of T2N0M0 breast carcinoma (tumor \u22643 cm in largest dimension)",
            "mapping_rationale": "Explicit statement of patient sex",
            "id": "67471cf7-edb5-4ef7-8817-e66a44bbc1fe"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "AgeMinimum",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "ageminimum",
              "display": "AgeMinimum"
            },
            "value": "18",
            "mapping_confidence": 1.0,
            "source_text_fragment": "minimumAge: 18 Years",
            "mapping_rationale": "Explicit minimum age for eligibility",
            "id": "46544cf0-9f0e-41d7-abb9-a2873ac55b92"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "AgeMaximum",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "agemaximum",
              "display": "AgeMaximum"
            },
            "value": "75",
            "mapping_confidence": 1.0,
            "source_text_fragment": "maximumAge: 75 Years",
            "mapping_rationale": "Explicit maximum age for eligibility",
            "id": "71322658-ae5d-4932-8f1b-6bba88bcc37c"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Segmental mastectomy or quadrantectomy (lumpectomy)",
            "mapping_confidence": 1.0,
            "source_text_fragment": "in patients with functional and cosmetic breast deformities post segmental mastectomy or quadrantectomy (lumpectomy)",
            "mapping_rationale": "Explicit mention of surgical procedures performed, which are standard treatments for breast cancer.",
            "id": "3ee2541c-1358-400e-acb6-08c2435f7962"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Lumpectomy",
            "mapping_confidence": 0.7,
            "source_text_fragment": "Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy",
            "mapping_rationale": "Lumpectomy is explicitly mentioned as a previous procedure, commonly associated with breast cancer treatment, but not explicitly stated for cancer here.",
            "id": "5f4bce3e-db43-4b7d-8efc-2c97a39222a9"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Radiation Therapy",
            "mapping_confidence": 0.7,
            "source_text_fragment": "Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy",
            "mapping_rationale": "Radiation therapy is explicitly mentioned as a possible previous treatment, commonly used in cancer care, but not explicitly stated for cancer here.",
            "id": "fff6e5f1-aecc-4dc2-9655-425810958b54"
          }
        ],
        "source_references": [],
        "validation": {
          "valid": true,
          "errors": [],
          "warnings": [],
          "compliance_score": 1.0
        },
        "metadata": {
          "pipeline_version": "Mcode_pipeline_v1",
          "engine_type": "LLM",
          "entities_count": 0,
          "mapped_count": 17,
          "compliance_score": 1.0,
          "token_usage": {
            "prompt_tokens": 855,
            "completion_tokens": 6680,
            "total_tokens": 7535
          },
          "aggregate_token_usage": {
            "prompt_tokens": 0,
            "completion_tokens": 0,
            "total_tokens": 0,
            "model_name": "",
            "provider_name": ""
          }
        },
        "error": null
      }
    }
  ],
  "failed_trials": []
}